Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 plus Anlotinib vs Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
NCT05145218Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of benmelstobart in ovarian cancer (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Disease progression-free survival up to 2 years and Overall survival up to 2 years. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05145218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145218.